A citation-based method for searching scientific literature

Alexandra Katsimardou, Konstantinos Imprialos, Konstantinos Stavropoulos, Alexandros Sachinidis, Michalis Doumas, Vasilios G Athyros. Expert Opin Pharmacother 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
284
100


Effect of N-acetylcysteine on sympathetic hyperinnervation in post-infarcted rat hearts.
Tsung-Ming Lee, Po-Yu Lai, Nen-Chung Chang. Cardiovasc Res 2010
35
100

Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study.
Leo Niskanen, David E Laaksonen, Jaana Lindström, Johan G Eriksson, Sirkka Keinänen-Kiukaanniemi, Pirjo Ilanne-Parikka, Sirkka Aunola, Helena Hämäläinen, Jaakko Tuomilehto, Matti Uusitupa. Diabetes Care 2006
69
100


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
399
100



6
100



Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
24
100

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease.
Oshini Shivakumar, Naveed Sattar, David C Wheeler. Nephrol Dial Transplant 2020
3
100

Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans.
Jeremy Bellien, Julie Favre, Michele Iacob, Ji Gao, Christian Thuillez, Vincent Richard, Robinson Joannidès. Hypertension 2010
81
100


Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-Ichi Hirata, Masataka Sata. Eur J Pharmacol 2020
14
100

Empagliflozin in type 1 diabetes.
Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout. Diabetes Metab Syndr Obes 2019
2
100

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2020
12
100

Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
R Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan, Suhaj Abdulsalim. Postgrad Med 2017
14
100

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
Eileen O'Meara, Michael McDonald, Michael Chan, Anique Ducharme, Justin A Ezekowitz, Nadia Giannetti, Adam Grzeslo, George A Heckman, Jonathan G Howlett, Sheri L Koshman,[...]. Can J Cardiol 2020
29
100

SGLT2 inhibitors - a potential treatment for Alport syndrome.
Holly Mabillard, John A Sayer. Clin Sci (Lond) 2020
3
100

Antiarrhythmic effect of lithium in rats after myocardial infarction by activation of Nrf2/HO-1 signaling.
Tsung-Ming Lee, Shinn-Zong Lin, Nen-Chung Chang. Free Radic Biol Med 2014
39
100

Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure.
Ting Liu, Eiki Takimoto, Veronica L Dimaano, Deeptankar DeMazumder, Sarah Kettlewell, Godfrey Smith, Agnieszka Sidor, Theodore P Abraham, Brian O'Rourke. Circ Res 2014
89
100

Renal hyperfiltration related to diabetes mellitus and obesity in human disease.
Alexa N Sasson, David Zi Cherney. World J Diabetes 2012
94
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Robert Rosenstein, Augustus Hough. N Engl J Med 2016
8
100

Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection.
Emile Andari, Samir Arnaout, Sami T Azar, Elie Chammas, Selim Jambart, Mounzer Saleh, Rita Nemr, Antoine Sarkis. Curr Diabetes Rev 2020
1
100





Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.
T Nojima, Y Matsubayashi, A Yoshida, H Suganami, T Abe, M Ishizawa, K Fujihara, S Tanaka, K Kaku, H Sone. Diabet Med 2020
3
100


Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.
Yun-Jing Zhang, Shi-Liang Han, Xi-Feng Sun, Shu-Xiang Wang, Hong-Yun Wang, Xiao Liu, Li Chen, Ling Xia. Medicine (Baltimore) 2018
8
100

Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition.
Anita T Layton, Volker Vallon, Aurélie Edwards. Am J Physiol Renal Physiol 2015
66
100

The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'.
Frederik H Verbrugge, Matthias Dupont, Paul Steels, Lars Grieten, Quirine Swennen, W H Wilson Tang, Wilfried Mullens. Eur J Heart Fail 2014
71
100

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
190
100

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
454
100


Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Hiddo J L Heerspink, Bergur V Stefansson, Glenn M Chertow, Ricardo Correa-Rotter, Tom Greene, Fan-Fan Hou, Magnus Lindberg, John McMurray, Peter Rossing, Roberto Toto,[...]. Nephrol Dial Transplant 2020
59
100

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
420
100

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
500
100

Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms.
Jennifer N Cooper, Jeanine M Buchanich, Ada Youk, Maria Mori Brooks, Emma Barinas-Mitchell, Molly B Conroy, Kim Sutton-Tyrrell. Atherosclerosis 2012
45
100

Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C J Dekkers, Ron T Gansevoort. Nephrol Dial Transplant 2020
11
100

Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
N N Hamouda, V Sydorenko, M A Qureshi, J M Alkaabi, M Oz, F C Howarth. Mol Cell Biochem 2015
34
100

Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.
Charalambos Vlachopoulos, Konstantinos Aznaouridis, Christodoulos Stefanadis. J Am Coll Cardiol 2010
100

Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis.
Steven M Pogwizd, Karin R Sipido, Fons Verdonck, Donald M Bers. Cardiovasc Res 2003
107
100

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
David R Matthews, Qiang Li, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, William R Hiatt, Mark Nehler, Elisa Fabbrini,[...]. Diabetologia 2019
45
100

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Arief Rahadian, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata. J Atheroscler Thromb 2020
9
100

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
473
100

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N Batchu, Verra G Yerra, Golam Kabir, Kerri Thai, Andrew Advani,[...]. Cardiovasc Diabetol 2020
10
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.